A pharmacokinetic study of radiprodil oral suspension in healthy adults comparing conventional venous blood sampling with two microsampling techniquesA phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1-4, as a single dose and multiple doses in patients with solid malignanciesBAY 1213790, a fully human IgG1 antibody targeting coagulation factor XIa: First evaluation of safety, pharmacodynamics, and pharmacokineticsKEYNOTE-025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1-positive advanced non-small-cell lung cancerYou BETer be aware - learnings from a negative Phase 1 studyA Phase 1 Randomized Study of Single Intravenous Infusions of the Novel Nitroxyl Donor BMS-986231 in Healthy VolunteersPhase I dose-escalation study of capmatinib (INC280) in Japanese patients with advanced solid tumorsA Study to Assess the Effect of Verinurad on the Electric Activity of the HeartDose Escalation Study of PF-07209326 in Healthy ParticipantsRLY-1971 in Subjects With Advanced or Metastatic Solid TumorsEvaluation of KAN-101 in Celiac DiseaseA Study to Test the Blood Concentration of 4 Padsevonil Product Variants and the Effect of Food on PadsevonilPhase 1 Study of Oral TP-1454Study to Assess Safety, Tolerability and Phamacokinetics of KAE609 Administered Intravenously in Healthy SubjectsStudy of SRF617 in Patients With Advanced Solid TumorsStudy of SRF388 in Patients With Advanced Solid Tumors
P921
Q61808405-1B677CCB-BD93-4459-8C0A-2B434F6FE463Q64109858-83CB2748-3D97-407D-B99E-CD212E8997C2Q64228864-AA06129C-66C4-4576-9FF0-8AA6122DB649Q64236602-463951F0-6682-47EE-B1D6-8935EEB208F3Q64256006-59C1AF86-B5B1-49F2-BFD1-260F146BBC28Q64258422-6B1E6B2F-2664-4782-9DDB-CD01972F5C6BQ64296860-CE5ACCB4-E718-4B48-9129-940C122342F1Q86258541-7A78C720-CCEE-426B-8D01-3ACECA5EC1BFQ86259663-F1AB30DB-22EA-4651-BC47-46646D565FA7Q86267025-B0B992F3-153B-409D-BBA9-ED2AC8DFA2FEQ86286052-65C64D3F-CEB0-45E6-9502-F0829D1726A4Q87932829-1CEA11DA-7B47-4D40-9043-D7835E55B7F2Q89153150-720F857A-8599-4130-9589-946FA4773970Q89154803-FF5BC95D-AADF-4916-9FD1-7CA731663CE2Q90693616-E8D5A7A2-20C5-4F7A-8D81-6556B31FB1CCQ93422369-EE46D129-506A-4B3E-8A64-A24BD9164A7D
P921
name
Phase 1
@en
type
label
Phase 1
@en
prefLabel
Phase 1
@en
P214
P244
P214
P244
no2013118642
P31
P625
Point (-76.995 38.882)
P7859
lccn-no2013118642